Nurix Therapeutics has Received FDA’s Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia / Arthur T. Sands, cancer, EMA PRIME Designation,

First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex